Lexaria Awards Share Incentive Related to Recent Patent Achievements

Lexaria Bioscience Corp. LXRP LXX:CNX, a drug delivery platform innovator, announces that it has issued a total of 355,000 restricted common shares as required by executive consulting agreements, shared by the Chief Executive Officer and the President of the Company.

The shares are required to be issued upon certain intellectual property achievements and patent application filings in March and April triggered the awards. As a result, 172,500 shares were awarded at an issue price of US$1.24; and 182,500 shares were awarded at an issue price of US$1.32. Cash compensation of US$185,200 designed to offset tax liabilities from the share award was also granted.

Lexaria currently has ~49 patents pending or granted around the world and has fostered an internal environment of intellectual creativity, incentivizing employees and consultants for successful patent progress. One year ago, the Company had only ~18 patents pending or granted.

In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.